Posted by Michael Wonder on 27 Jun 2023
AC Immune receives FDA fast track designation for anti-amyloid beta active immunotherapy, ACI-24.060, to treat Alzheimer’s disease
27 June 2023 - Initial PET data on amyloid plaque reduction in Alzheimer's disease expected H1, 2024.
AC Immune today announced that it has received fast track designation from the US FDA for its wholly owned anti-amyloid beta active immunotherapy (vaccine) candidate, ACI-24.060, for treatment of Alzheimer’s disease.
